Product Information
ADVAIR HFA 230-21 MCG INHALER is a brand product labeled by GlaxoSmithKline LLC, priced at $30.6070 per GM under NDC 00173071722. Its NADAC has been published 383 times since Nov 28, 2013.
FDA first approved this application on Jun 8, 2006.
Strength
230; 21 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173071722
Classification
Brand
Dosage Form
AEROSOL, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEApproval Type
New Drug (NDA)
FDA Application
NDA021254FDA Approved
6/8/2006
On Market Since
3/6/2009
Pharmacological Classes
Price Statistics
The NADAC for ADVAIR HFA 230-21 MCG INHALER has been published 383 times since Nov 28, 2013, and over the history we have for it it has risen 17.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $30.6070 per GM |
|---|---|
| All-time high | $38.0902 (Jan 10, 2018) |
| All-time low | $26.0473 (Nov 28, 2013) |
| 52-week high | $30.6487 |
| 52-week low | $30.4921 |
| Median price | $30.5992 |
| Average price | $31.8293 |
| Largest weekly change | -19.1% (Jun 19, 2024) |
| Weeks tracked | 383 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 12% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ADVAIR HFA 230-21 MCG INHALER?
The current National Average Drug Acquisition Cost (NADAC) for ADVAIR HFA 230-21 MCG INHALER, manufactured by GlaxoSmithKline LLC, is $30.6070 per GM (NDC 00173071722), effective Aug 19, 2026.
How has the price of ADVAIR HFA 230-21 MCG INHALER changed over time?
Over the history we have for it, the NADAC for ADVAIR HFA 230-21 MCG INHALER has risen 17.5%. It has been tracked across 383 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ADVAIR HFA 230-21 MCG INHALER?
Since Nov 28, 2013, the NADAC for ADVAIR HFA 230-21 MCG INHALER has ranged from a low of $26.0473 (Nov 28, 2013) to a high of $38.0902 (Jan 10, 2018), with a median of $30.5992 per GM.
Are there cheaper alternatives to ADVAIR HFA 230-21 MCG INHALER?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FLUTICASONE-SALMETEROL 230-21, is $27.0769 per GM — about 12% below ADVAIR HFA 230-21 MCG INHALER.
Who manufactures ADVAIR HFA 230-21 MCG INHALER?
ADVAIR HFA 230-21 MCG INHALER (NDC 00173071722) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.